Cempra Pharmaceuticals appears to be one of the first companies exploring the newly enacted “limited use” pathway for novel antibiotics. The company cited the approach as an option for fusidic acid for use against MRSA – but it sounds like it may also be on the table for the company’s recently rejected solithromycin.
Cempra Inc. hopes to use the newly enacted “Limited Use” antibiotic development pathway to help move its antibiotic Taksta (fusidic acid) through the US FDA to approval in the relatively near future.
On Feb. 24, the company reported a positive Phase III study of the drug in skin and skin structure infections....